Dr. Neelapu on Updated ZUMA-1 Findings in Non-Hodgkin Lymphoma
December 12th 2017
Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.